Incidence of breast cancer in China has risen much more quickly over the past two decades than it has in other countries, mainly due to the general aging of the population and increased adoption of Westernized diets.
New York, NY (PRWEB) September 30, 2013
China’s newly diagnosed female breast cancer patients are expected to outnumber those in the United States for the first time in 2015, according to new data from Kantar Health’s CancerMPact® Patient Metrics – Expanded Markets. The number of newly diagnosed women in China is expected to continue to increase to more than 300,000 per year by 2040.
The number of breast cancer patients diagnosed annually has increased by over 50 percent since 2004. In 2012 China had 225,000 new cases of breast cancer, compared with 149,000 in 2004. In the U.S., the number of patients newly diagnosed with breast cancer increased by only 17 percent over this same period. Incidence of breast cancer is still much higher in China’s urban population than in rural areas, but the rural incidence rate has been growing faster in recent years, narrowing the gap between urban and rural areas. In addition, the mean age of diagnosis of breast cancer is approximately nine years younger in China than it is in the U.S. or Europe.
These data were drawn from CancerMPact® Patient Metrics – Expanded Markets, which builds upon Kantar Health's gold-standard epidemiology for the G7 markets by combining epidemiologic data and analysis to estimate incidence by stage, five-year prevalence and treatable patients in 10 tumor types in Argentina, Brazil, Canada, China, India, Mexico, Russia, South Korea, Taiwan and Turkey:
- Hepatocellular carcinoma
- Multiple myeloma
- Non-Hodgkin’s lymphoma
- Non-small cell lung
“Historically, China has had one of the lowest incidence rates of breast cancer, especially when compared with Western countries,” said David Robinson, Vice President, Kantar Health. “However, incidence has risen much more quickly over the past two decades than it has in other countries, mainly due to the general aging of the population and increased adoption of Westernized diets. Our data suggest that these factors will likely lead to continued increases in incidence.”
CancerMPact® is an invaluable oncology decision support resource for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This resource is composed of web-based integrated modules: Treatment Practices and Evolution (Treatment Architecture and Future Trends and Insights) and Patient Metrics (Patient Metrics – G7, Patient Metrics – Expanded Markets and Biomarker Analysis).
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.